161 related articles for article (PubMed ID: 25529282)
1. Erythropoiesis-stimulating agents: dose and mortality risk.
Bellinghieri G; Condemi CG; Saitta S; Trifirò G; Gangemi S; Savica V; Buemi M; Santoro D
J Ren Nutr; 2015 Mar; 25(2):164-8. PubMed ID: 25529282
[TBL] [Abstract][Full Text] [Related]
2. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
3. Erythropoiesis-stimulating agent responsiveness and mortality in hemodialysis patients: results from a cohort study from the dialysis registry in Japan.
Fukuma S; Yamaguchi T; Hashimoto S; Nakai S; Iseki K; Tsubakihara Y; Fukuhara S
Am J Kidney Dis; 2012 Jan; 59(1):108-16. PubMed ID: 21890255
[TBL] [Abstract][Full Text] [Related]
4. Low hemoglobin levels and hypo-responsiveness to erythropoiesis-stimulating agent associated with poor survival in incident Japanese hemodialysis patients.
Akizawa T; Saito A; Gejyo F; Suzuki M; Nishizawa Y; Tomino Y; Tsubakihara Y; Akiba T; Hirakata H; Watanabe Y; Kawanishi H; Bessho M; Udagawa Y; Aoki K; Uemura Y; Ohashi Y;
Ther Apher Dial; 2014 Oct; 18(5):404-13. PubMed ID: 24571446
[TBL] [Abstract][Full Text] [Related]
5. Association of Erythropoietin-Stimulating Agent Responsiveness with Mortality in Hemodialysis and Peritoneal Dialysis Patients.
Bae MN; Kim SH; Kim YO; Jin DC; Song HC; Choi EJ; Kim YL; Kim YS; Kang SW; Kim NH; Yang CW; Kim YK
PLoS One; 2015; 10(11):e0143348. PubMed ID: 26588085
[TBL] [Abstract][Full Text] [Related]
6. Mortality and cardiovascular morbidity associated with haemoglobin levels: a pooled analysis of randomised controlled trials.
Locatelli F; de Francisco A; Deray G; Fliser D; Armstrong G; Dougherty FC; Ehrhard P
Nephron Clin Pract; 2014; 128(3-4):323-32. PubMed ID: 25503585
[TBL] [Abstract][Full Text] [Related]
7. Types of erythropoiesis-stimulating agents and risk of end-stage kidney disease and death in patients with non-dialysis chronic kidney disease.
Minutolo R; Garofalo C; Chiodini P; Aucella F; Del Vecchio L; Locatelli F; Scaglione F; De Nicola L
Nephrol Dial Transplant; 2021 Jan; 36(2):267-274. PubMed ID: 32829405
[TBL] [Abstract][Full Text] [Related]
8. The Korean Clinical Research Center for End-Stage Renal Disease Study Validates the Association of Hemoglobin and Erythropoiesis-Stimulating Agent Dose with Mortality in Hemodialysis Patients.
Kwon O; Jang HM; Jung HY; Kim YS; Kang SW; Yang CW; Kim NH; Choi JY; Cho JH; Kim CD; Kim YL; Park SH;
PLoS One; 2015; 10(10):e0140241. PubMed ID: 26452232
[TBL] [Abstract][Full Text] [Related]
9. Comparative Safety of Long-Acting vs. Short-Acting Erythropoiesis-Stimulating Agents Among Patients Undergoing Hemodialysis.
Desai R; Unigwe I; Riaz M; Smith SM; Shukla AM; Mohandas R; Jeon N; Park H
Clin Pharmacol Ther; 2024 Jul; 116(1):217-224. PubMed ID: 38629679
[TBL] [Abstract][Full Text] [Related]
10. Inflammation, high ferritin, and erythropoietin resistance in indigenous maintenance hemodialysis patients from the Top End of Northern Australia.
Majoni SW; Ellis JA; Hall H; Abeyaratne A; Lawton PD
Hemodial Int; 2014 Oct; 18(4):740-50. PubMed ID: 24766376
[TBL] [Abstract][Full Text] [Related]
11. Association of mean weekly epoetin alfa dose with mortality risk in a retrospective cohort study of Medicare hemodialysis patients.
Weinhandl ED; Gilbertson DT; Collins AJ
Am J Nephrol; 2011; 34(4):298-308. PubMed ID: 21829009
[TBL] [Abstract][Full Text] [Related]
12. Hyporesponsiveness to erythropoiesis-stimulating agents and renal survival in non-dialysis CKD patients.
Minutolo R; Conte G; Cianciaruso B; Bellizzi V; Camocardi A; De Paola L; De Nicola L
Nephrol Dial Transplant; 2012 Jul; 27(7):2880-6. PubMed ID: 22319218
[TBL] [Abstract][Full Text] [Related]
13. Types of Erythropoietin-Stimulating Agents and Mortality among Patients Undergoing Hemodialysis.
Sakaguchi Y; Hamano T; Wada A; Masakane I
J Am Soc Nephrol; 2019 Jun; 30(6):1037-1048. PubMed ID: 31015255
[TBL] [Abstract][Full Text] [Related]
14. Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease.
Carrero JJ; Bárány P; Yilmaz MI; Qureshi AR; Sonmez A; Heimbürger O; Ozgurtas T; Yenicesu M; Lindholm B; Stenvinkel P
Nephrol Dial Transplant; 2012 Feb; 27(2):709-15. PubMed ID: 21617198
[TBL] [Abstract][Full Text] [Related]
15. Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study.
Panichi V; Rosati A; Bigazzi R; Paoletti S; Mantuano E; Beati S; Marchetti V; Bernabini G; Grazi G; Rizza GM; Migliori M; Giusti R; Lippi A; Casani A; Barsotti G; Tetta C;
Nephrol Dial Transplant; 2011 Aug; 26(8):2641-8. PubMed ID: 21325348
[TBL] [Abstract][Full Text] [Related]
16. Serum 25(OH)-cholecalciferol concentration is associated with hemoglobin level and erythropoietin resistance in patients on maintenance hemodialysis.
Kiss Z; Ambrus C; Almasi C; Berta K; Deak G; Horonyi P; Kiss I; Lakatos P; Marton A; Molnar MZ; Nemeth Z; Szabo A; Mucsi I
Nephron Clin Pract; 2011; 117(4):c373-8. PubMed ID: 21071961
[TBL] [Abstract][Full Text] [Related]
17. Comparative mortality risk of anemia management practices in incident hemodialysis patients.
Brookhart MA; Schneeweiss S; Avorn J; Bradbury BD; Liu J; Winkelmayer WC
JAMA; 2010 Mar; 303(9):857-64. PubMed ID: 20197532
[TBL] [Abstract][Full Text] [Related]
18. Predialysis anemia management and outcomes following dialysis initiation: A retrospective cohort analysis.
Wetmore JB; Li S; Yan H; Xu H; Peng Y; Sinsakul MV; Liu J; Gilbertson DT
PLoS One; 2018; 13(9):e0203767. PubMed ID: 30256836
[TBL] [Abstract][Full Text] [Related]
19. Relationships among the Dosage of Erythropoiesis-Stimulating Agents, Erythropoietin Resistance Index, and Mortality in Maintenance Hemodialysis Patients.
Pan S; Zhao DL; Li P; Sun XF; Zhou JH; Song KK; Wang Y; Miao LN; Ni ZH; Lin HL; Liu FY; Li Y; He YN; Wang NS; Wang CL; Zhang AH; Chen MH; Yang XP; Deng YY; Shao FM; Fu SX; Fang JA; Cai GY; Chen XM
Blood Purif; 2022; 51(2):171-181. PubMed ID: 34175850
[TBL] [Abstract][Full Text] [Related]
20. The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now?
Singh AK
Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S5-13. PubMed ID: 19010260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
